In Vitro Selection and Characterization of Tecovirimat-resistant Mpox Virus

Clicks: 3
ID: 314049
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #287 of 431 articles by views in The Journal of infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 431 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Mpox virus (MPXV) is the causative agent of mpox, a disease characterized by skin lesions, and remains a global threat since the recent 2022 outbreak. Tecovirimat is an antiviral agent that inhibits MPXV replication in vitro and in vivo by targeting the viral phospholipase VP37 protein and blocking viral envelope wrapping. Although tecovirimat has been administered to many mpox patients, the emergence of tecovirimat-resistant MPXVs carrying mutations in the VP37 protein has been reported, particularly in immunocompromised individuals. However, the impact of these respective mutations on drug susceptibility and viral fitness have not been fully characterized. METHODS: Tecovirimat was applied as a selective pressure in vitro to isolate MPXV variants carrying clinically observed VP37 substitutions. Drug susceptibility among the major VP37 mutations was compared, and the cellular fitness of the isolated viruses was evaluated. RESULTS: The VP37-N267D and -Y258C mutants showed markedly reduced susceptibility to tecovirimat compared with the VP37-I372N and -T245I (+I7L-A388S) mutants, while retaining susceptibility to an alternative anti-MPXV agent, brincidofovir. The VP37-I372N, T245I (+I7L-A388S), Y258C, and N267D mutants exhibited viral fitness comparable to that of the parental virus in A549 and Vero cells, as well as in MRC-5 and HaCaT cells. CONCLUSIONS: These findings provide insights into the phenotype of each VP37 mutation and emphasize the importance of developing antivirals with distinct mechanisms of action to effectively combat tecovirimat-resistant MPXV.
Reference Key
openalex_W7161598535 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kei Konishi, Haruka Maeda, Misato Shibazaki, Takao Shishido, Manabu Igarashi, W.W. Hall, Michihito Sasaki, Yasuko Orba, Hirofumi Sawa, Akihiko Sato
Journal The Journal of infectious diseases
Year 2026
DOI
10.1093/infdis/jiag222
URL
https://doi.org/10.1093/infdis/jiag222
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.